Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MX1 | Unknown | Unknown | Nelfinavir | 12667.174 | uM | 6.93420 | 10.10980 | -0.9543 | -1.0000 | 2.9138 | 0.1831 | 0.990 | 0.8129 | |||
| EFM-192B | HER2amp | Luminal | Torkinib | 15387.211 | uM | 0.00291 | 0.01240 | -0.6500 | -0.6119 | 0.5521 | 1.0170 | 0.9955 | 1.2404 | |||
| LY2 | HR+ | Luminal | Ribavirin | 15391.211 | uM | inf | inf | 0.9725 | 0.9725 | 0.0000 | 0.0076 | -0.0134 | 1.2835 | |||
| HCC1143 | TNBC | Basal A | Ribavirin | 15349.211 | uM | inf | inf | 0.8845 | 0.8845 | 0.0000 | 0.0438 | -0.0616 | 1.2538 | |||
| HCC38 | TNBC | Basal B | Mebendazole | 12617.174 | uM | 0.35225 | 0.53461 | -0.3927 | -0.2560 | 0.9909 | 0.4554 | 0.9683 | 1.5935 | |||
| SUM1315MO2 | TNBC | Basal B | Methylglyoxal | 13197.184 | uM | 477.56670 | 843.97530 | -0.9998 | -0.9846 | 1.9113 | 0.6795 | 0.9941 | 0.5530 | |||
| MDA-MB-134-VI | HR+ | Luminal | Torkinib | 15355.211 | uM | 0.00026 | 0.00531 | -0.8198 | -0.8282 | 0.3225 | 1.2019 | 0.9869 | 1.0584 | |||
| HCC1143 | TNBC | Basal A | 2-deoxyglucose | 13099.177 | uM | 998.14080 | 1000.00000 | -0.0218 | -0.0047 | 5.0000 | 0.0854 | 0.7290 | 0.7419 | |||
| SUM1315MO2 | TNBC | Basal B | Methylglyoxal | 13520.184 | uM | 567.6950 | 786.82260 | -0.9992 | -0.9966 | 3.3588 | 0.6425 | 0.9974 | 0.6738 | |||
| MDA-MB-453 | TNBC | Luminal | Mebendazole | 13562.174 | uM | 0.10597 | 0.12962 | -0.3553 | -0.2507 | 2.0171 | 0.6156 | 0.9838 | 0.7219 | |||
| CAMA-1 | HR+ | Luminal | Torkinib | 15348.211 | uM | 0.00176 | 0.01477 | -0.8919 | -0.9141 | 0.4883 | 1.1876 | 0.9886 | 0.7490 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 13125.174 | uM | 0.25333 | 0.32539 | -0.2292 | -0.1705 | 1.1722 | 0.5214 | 0.9620 | 0.9685 | |||
| Hs 578T | TNBC | Basal B | Torkinib | 15352.211 | uM | 0.09021 | 0.26878 | -0.3566 | -0.4047 | 0.5431 | 0.5802 | 0.9760 | 2.5357 | |||
| BT-474 | HER2amp | Luminal | Methylglyoxal | 13492.184 | uM | 377.06610 | 1000.00000 | -0.9884 | -0.9163 | 1.0675 | 0.6077 | 0.9794 | 0.9589 | |||
| LY2 | HR+ | Luminal | Torkinib | 15391.211 | uM | 0.00743 | 0.00789 | -0.0237 | -0.0145 | 0.4813 | 0.6703 | 0.9914 | 1.2835 | |||
| MCF12A | NM | Basal B | Pertuzumab | 7489.102 | mg/ml | inf | 125.00000 | 0.8728 | 0.5007 | 0.2455 | 0.0447 | 0.7417 | 2.4234 | |||
| BT-474 | HER2amp | Luminal | Nelfinavir | 13125.174 | uM | 10.470 | 16.79570 | -0.6639 | -1.0000 | 2.3245 | 0.2049 | 0.9671 | 0.9685 | |||
| HCC1187 | TNBC | Basal A | Mebendazole | 12696.174 | uM | 0.16082 | 0.25668 | -0.9919 | -0.9418 | 2.2652 | 0.9298 | 0.9674 | 0.6299 | |||
| BT-20 | TNBC | Basal A | Pertuzumab | 5903.102 | mg/ml | inf | inf | 0.9324 | 0.9324 | 0.0000 | -0.0074 | -0.0405 | 1.2557 | |||
| HCC1187 | TNBC | Basal A | Methylglyoxal | 13726.184 | uM | 0.99124 | 16.40040 | -1.0000 | -1.0000 | 0.3915 | 1.2606 | 0.7991 | 0.3574 | |||
| HCC1187 | TNBC | Basal A | Nelfinavir | 12696.174 | uM | 5.83210 | 8.5520 | -0.9972 | -1.0000 | 2.8701 | 0.3497 | 0.9263 | 0.6299 | |||
| MDA-MB-453 | TNBC | Luminal | Mebendazole | 12964.174 | uM | 0.21977 | 0.29241 | -0.4032 | -0.2943 | 1.6205 | 0.5795 | 0.9637 | 0.7885 | |||
| MCF12A | NM | Basal B | Ribavirin | 15354.211 | uM | inf | inf | 0.7146 | 0.7146 | 0.0000 | 0.0912 | 0.5457 | 2.0320 | |||
| SUM1315MO2 | TNBC | Basal B | Ribavirin | 15401.211 | uM | inf | inf | 0.9740 | 0.9740 | 0.0000 | 0.0925 | 0.0630 | 0.4079 | |||
| MCF 10A | NM | Basal B | Chloroquine | 12944.177 | uM | 17.43960 | 43.85410 | -0.2432 | -1.0000 | 1.1914 | 0.2250 | 0.7720 | 2.0477 |